

Building a Bio-economy

International Best Practices, Lessons Learned and Evidence from the Field

Prof Meir Pugatch

IPKM Chair, Univ. of Maastricht;
Managing Director, Pugatch Consilium

Opening Plenary


June 20, 2017

BIO Convention

San Diego, CA




Seven enabling factors for biopharmaceutical innovation



Source: Pugatch Consilium (2017)

When it comes to enabling innovation, some are near the summit while others are just starting the climb...

Biopharmaceutical Competitiveness & Investment (BCI) Survey, 4th edition, 2017



Market access, IP and localization = key policy gaps


Biopharmaceutical Competitiveness & Investment (BCI) Survey 2017 Scores

Newcomer Markets




Policy conditions affect competitiveness in “mature” markets too

Biopharmaceutical Competitiveness & Investment (BCI) Survey 2017 Scores Mature Markets




Why do policy conditions matter: \$100 billion reasons

Clinical trials intensity around the globe



* As registered in Clinicaltrials.gov database in June 2017

IP rights, innovation & economic activity



Thank you!